Lab-on-a-chip for multiplexed newborn screening of lysosomal storage disorders

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$188,364.00
Award Year:
2007
Program:
SBIR
Phase:
Phase I
Contract:
1R43HD057713-01
Award Id:
85780
Agency Tracking Number:
HD057713
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
ADVANCED LIQUID LOGIC, 615 Davis Dr., Suite 800, RESEARCH TRIANGLE PARK, NC, 27709
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
140695474
Principal Investigator:
VAMSEE PAMULA
(919) 287-9010
VKP@LIQUID-LOGIC.COM
Business Contact:
RICHARD WEST
() -
information@liquid-logic.com
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): Newborn screening is currently performed by collecting dried bloodspots from infants and then sending them to a lab for analysis. There is an increasing necessity to screen for a number of disease conditions for which therapies are becoming available. Lysosomal storage diseases alone number greater than 40. There is a need to minimize the blood collected for screening purposes while maximizing the number of conditions screened. Also, conventional laboratory analy sis of blood samples in a birthing center is impractical. An automated, inexpensive, multi-analyte and multiplexed newborn screening analyzer will help reduce the blood analysis volume, reduce the time-to-result, and make the analyzer available at the point-of- delivery (birthing centers). Based on Advanced Liquid Logic's previous demonstrations of digital microfluidic manipulation of nanoliter-sized droplets of enzymatic reagents and sample for dispensing from on-chip reservoirs, high speed transpo rt, mixing, splitting and dilution, and absorbance, fluorescence, and luminescence detection of the assays, a disposable lab-on-a-chip will be developed. Ultimately, a disposable lab-on-a-chip for newborn screening will be developed where one punch from th e dried blood spot or fresh blood will be the input to the system and it outputs the screening results in a completely automated fashion. Phase I work will focus on fabricating a microfluidic platform upon which microliters of dried blood spot extr acts, reference standards, and reagent droplets will be dispensed, transported, mixed, assayed, and disposed. Fluorescence assays for determining activities of enzymes involved in Pompe, Fabry, and Hurler diseases will be transitioned to droplet-based form at. Demonstration of these enzymatic assays establishes the feasibility of a digital microfluidic chip for newborn screening.Advanced Liquid Logic, Inc. is developing a lab-on-a-chip that integrates clinical chemistry, immunoassays, DNA amplification, and DNA sequencing on its proprietary digital (droplet-based) microfluidic platform for clinical diagnostics. The proposed project aims at demonstrating the feasibility of performing newborn screening for lysosomal storage disorders including Pompe, Fabry, and Hurler diseases from a single dried blood spot obtained from the heelstick of a newborn using a microfluidic lab-on-a-chip.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government